Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Posted by Scott Moore on Jul 15th, 2026

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 37,772 shares, a drop of 48.4% from the June 15th total of 73,164 shares. Based on an average daily volume of 299,767 shares, the short-interest ratio is currently 0.1 days. Currently, 2.2% of the shares of the company are sold short.

Lakewood-Amedex Biotherapeutics Trading Down 3.6%

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.09 on Wednesday, hitting $2.46. The stock had a trading volume of 953,490 shares, compared to its average volume of 308,918. The firm has a market capitalization of $4.31 million and a PE ratio of -1.21. Lakewood-Amedex Biotherapeutics has a twelve month low of $2.10 and a twelve month high of $98.20. The company has a 50 day moving average price of $8.96.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Check Out Our Latest Report on LABT

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.